Pfizer’s JAK inhibitor Cibinqo authorised in UK to treat atopic dermatitis
Cibinqo (abrocitinib) is a once-daily oral JAK1 inhibitor indicated for the treatment of moderate to severe atopic dermatitis…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Sep 21
Cibinqo (abrocitinib) is a once-daily oral JAK1 inhibitor indicated for the treatment of moderate to severe atopic dermatitis…
07 Sep 21
Hetero will manufacture the drug at its facility in Hyderabad and commercialise it in India by the end…
07 Sep 21
EMA’s human medicines committee (CHMP) is expected to undertake an accelerated assessment of data submitted by Pfizer and…
02 Sep 21
The US FDA approval of Brukinsa was based on results from the Phase 3 ASPEN trial, which evaluated…
30 Aug 21
The EC approval is based on data from the vosoritide clinical development programme, including results from the Phase…
27 Aug 21
The drug was already approved in the US and the European Union for the treatment of CKD in…
27 Aug 21
The court ruled that certain parts of the patent were invalid and that the earlier jury verdict was…
26 Aug 21
According to the Phase 3 data, a booster dose of Comirnaty elicited significant immune responses, with a favourable…
24 Aug 21
Comirnaty is said to be the first Covid-19 vaccine to receive full FDA approval and is indicated to…
23 Aug 21
Zydus claims that its ZyCoV-D is the world's first plasmid DNA vaccine for Covid-19, with well-established safety, efficacy…